期刊
JOURNAL OF THE DERMATOLOGY NURSES ASSOCIATION
卷 14, 期 1, 页码 20-27出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/JDN.0000000000000661
关键词
Atopic Dermatitis; Pruritus; Biologics; Research Summaries
类别
Atopic dermatitis (AD) is a common chronic inflammatory skin disease characterized by itching and dryness. Recent studies have identified genetic risk factors, guiding the treatment options for AD. Current treatments include topical agents, systemic biologics, and Janus kinase inhibitors.
Atopic dermatitis (AD) is defined as a chronic inflammatory skin disease characterized by pruritus and xerosis. AD is the most common inflammatory skin disease, affecting about 200 million people worldwide. Although AD is diagnosed in all ages and races, there are distinct findings associated with the different age groups that can help guide the diagnosis. Recent, robust studies have identified hereditary and genetic risk factors, which have guided the treatment options for AD. This includes various topical agents, a new generation of systemic biologics (dupilumab, tralokinumab, and lebrikizumab), and Janus kinase inhibitors (abrocitinib and baricitinib). Here, we describe some of the common clinical manifestations, hypothesized mechanisms, and current therapeutic treatment options for patients with moderate-to-severe AD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据